Data Insights

YL-13027 by Shanghai Yingli Pharmaceutical for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval

YL-13027 is under clinical development by Shanghai Yingli Pharmaceutical and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas....

Likelihood of Approval and Phase Transition Success Rate Model - YL-13027 in Metastatic Adenocarcinoma of The Pancreas

Data Insights

Linperlisib by Shanghai Yingli Pharmaceutical for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

Linperlisib is under clinical development by Shanghai Yingli Pharmaceutical and currently in Phase II for T-Cell Acute Lymphocytic Leukemia (T-Cell...

Likelihood of Approval and Phase Transition Success Rate Model - Linperlisib in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)

Data Insights

Linperlisib by Shanghai Yingli Pharmaceutical for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval

Linperlisib is under clinical development by Shanghai Yingli Pharmaceutical and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According...

Likelihood of Approval and Phase Transition Success Rate Model - Linperlisib in Peripheral T-Cell Lymphomas (PTCL)

Data Insights

Linperlisib by Shanghai Yingli Pharmaceutical for Natural Killer Cell Lymphomas: Likelihood of Approval

Linperlisib is under clinical development by Shanghai Yingli Pharmaceutical and currently in Phase II for Natural Killer Cell Lymphomas. According...

Likelihood of Approval and Phase Transition Success Rate Model - Linperlisib in Natural Killer Cell Lymphomas

Data Insights

YL-13027 by Shanghai Yingli Pharmaceutical for Solid Tumor: Likelihood of Approval

YL-13027 is under clinical development by Shanghai Yingli Pharmaceutical and currently in Phase I for Solid Tumor. According to GlobalData,...

Data Insights

Linperlisib by Shanghai Yingli Pharmaceutical for Hematological Tumor: Likelihood of Approval

Linperlisib is under clinical development by Shanghai Yingli Pharmaceutical and currently in Phase I for Hematological Tumor. According to GlobalData,...

Data Insights

Linperlisib by Shanghai Yingli Pharmaceutical for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval

Linperlisib is under clinical development by Shanghai Yingli Pharmaceutical and currently in Phase II for Anaplastic Large Cell Lymphoma (ALCL)....

Data Insights

Linperlisib by Shanghai Yingli Pharmaceutical for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy: Likelihood of Approval

Linperlisib is under clinical development by Shanghai Yingli Pharmaceutical and currently in Phase II for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy....

Data Insights

Linperlisib by Shanghai Yingli Pharmaceutical for Follicular Lymphoma: Likelihood of Approval

Linperlisib is under clinical development by Shanghai Yingli Pharmaceutical and currently in Phase II for Follicular Lymphoma. According to GlobalData,...

Data Insights

Linperlisib by Shanghai Yingli Pharmaceutical for T-Cell Leukemia: Likelihood of Approval

Linperlisib is under clinical development by Shanghai Yingli Pharmaceutical and currently in Phase I for T-Cell Leukemia. According to GlobalData,...